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Abstract
Highly pathogenic avian influenza viruses (HPAIVs) cause severe disease in humans. There are no effective vaccines or
antiviral therapies currently available to control fatal outbreaks due in part to the lack of understanding of virus-mediated
immunopathology. In our study, we used hemagglutinin (HA) of H5N1 virus to investigate the related signaling pathways
and their relationship to dysregulated innate immune reaction. We found the HA of H5N1 avian influenza triggered an
abnormal innate immune signalling in the pulmonary epithelial cells, through an unusual process involving activation of
Janus kinase 3 (JAK3) that is exclusively associated with cc chain and is essential for signaling via all cc cytokine receptors. By
using a selective JAK3 inhibitor and JAK3 knockout mice, we have, for the first time, demonstrated the ability to target
active JAK3 to counteract injury to the lungs and protect immunocytes from acute hypercytokinemia -induced destruction
following the challenge of H5N1 HA in vitro and in vivo. On the basis of the present data, it appears that the efficacy of
selective JAK3 inhibition is likely based on its ability to block multiple cytokines and protect against a superinflammatory
response to pathogen-associated molecular patterns (PAMPs) attack. Our findings highlight the potential value of selective
JAK3 inhibitor in treating the fatal immunopathology caused by H5N1 challenge.
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Introduction
Highly pathogenic avian influenza (HPAI) is an extremely
contagious, multi-organ systemic disease [1]. One among multiple
subtypes of influenza virus A, H5N1 viruses have caused 520
laboratory-confirmed infections in 15 countries, 307 of which were
fatal, resulting in a fatality rate of approximately 60% since 2003
[2], which should be considered to have been a potentially serious
pandemic threat [3]. Clinical observations indicated that acute
lung injury and multiple organ dysfunction were the direct causes
of death in H5N1-infected humans [4–5]. Laboratory findings
revealed low peripheral blood T-lymphocyte counts and high
chemokine and cytokine levels in H5N1-infected individuals,
particularly in those who died. Levels of IP-10, MIG and MCP-1
(chemoattractants of monocytes and macrophages that are pro-
duced in bronchial epithelial cells and alveolar macrophages
[6–8]) were elevated in patients with avian and human subtypes of
influenza but were higher in H5N1-infected individuals and
particularly high in those who died [6]. Levels of the neutrophil
chemoattractant interleukin (IL)-8 were also elevated in H5N1-
infected individuals, particularly in those who died [6]. The IL-8
chemokine is produced by bronchial epithelial cells and may
function in the pathogenesis of acute respiratory distress syndrome
(ARDS) [9], which may be particularly relevant to H5N1 in-
fluenza, as progression to respiratory failure is associated with the
development of ARDS [10–11]. The clinical and pathological
features in H5N1-infected humans and animal models suggest that
high levels of viral replication combined with early robust host
responses play a key role in pneumonia severity and outcome
[6,10–16].
The innate immune response of the cell is the first line of
defence against viruses. Increasing evidence points to a key role
of the innate immune system with its pattern recognition receptors
(PRRs) in both infectious and non-infectious lung diseases, acute
lung injury, pneumoconiosis and asthma [17]. Of PRRs, the well-
known Toll-like receptors (TLRs) are expressed in alveolar
macrophages, lung epithelial cells and in intraepithelial dendritic
cells (DCs), which are either located at the cell surface or in
endosomal membranes. These cells respond to infections by
sensing pathogen-associated molecular patterns (PAMPs) and
respond to endogenous molecules (danger-associated molecular
patterns [DAMPs]) that are released after tissue damage [17–18].
The TLRs recruit different adapter molecules and initiate
signalling pathways leading to the activation of NF-kB–dependent
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type I interferon (IFNa/b) expression [18–19]. An analysis of
sections from the human respiratory tract demonstrated that
H5N1 attached to the apical cell membrane of bronchiolar cells,
type II pneumocytes and alveolar macrophages [20]. Therefore,
activation of TLRs expressed in type II pneumocytes could help
mediate the response to H5N1 viruses [21], contributing to the
promotion of a destructive host immunity [22–24]. Although
neuraminidase inhibitors are effective in treating avian influenza,
especially if given within 48 h of infection, it is more difficult to
prevent the resultant hypercytokinemia from developing if the
patient does not seek timely medical assistance.
Corticosteroids have been used in some patients with HPAI
H5N1, but no definitive role for steroids has been determined [25–
26]. The evidence for corticosteroid use in other severe viral
pneumonias, including varicella-zoster virus infection and severe
acute respiratory syndrome (SARS), is also insufficient [7–8].
Several studies involving patients with sepsis and ARDS have
suggested that high-dose corticosteroids actually increase the risk
of secondary infections [27]. Thus, there is an urgent need to find
ways of treating acute hypercytokinemia without compromising
overall immunity. Because hemagglutinin, the major surface
glycoprotein of H5N1, is responsible for viral binding to host
receptors and initiating immediate signalling transduction upon
viral invasion [28], the recombinant HA of H5N1 avian influenza
virus (AIV) was used in the present study to investigate the signal
transduction mechanisms for the dysregulated innate immune
reaction. We have demonstrated that challenging respiratory
epithelial cells with H5N1 HA exploited the JAK2/3/STAT1 and
NF-kB signalling axis and resulted in a large release of cytokines,
initiating a destructive innate immune response at early stages.
Additionally, we found that a selective JAK3 inhibitor (JAK3inh)
targeted to the key signal molecule in the inflammatory signal
cascades has potential roles in the treatment of the inflammatory
disorders, thereby protecting against a superinflammatory re-
sponse to PAMPs attack.
Results
Morphological changes of the cultured pulmonary
epithelial cells after exposure to the recombinant HA of
AIV H5N1
The cultured human pulmonary epithelial A549 cells were
challenged with recombinant HA at 40 mg/ml. After 12 h of
stimulation, the cells became swollen, rounded and irregular in
size and shape with the appearance of intracellular vacuoles
(Figure 1Bb) whereas the control cells did not (Figure 1Ba).
Activation of JAK/STAT and NF-kB signalling in relation
with innate immune inflammation in HA-challenged
pulmonary epithelial cells
We next tested if the recombinant HA could induce activation of
JAK/STAT and NF-kB signal pathways, which are responsible for
transcriptional activation of chemokines/cytokines genes and lead
to an innate immune response against pathogens. We found that
A549 cells exposed to HA have increasing levels of phosphorylation
of JAK2, JAK3, STAT1 and NF-kB( Figure 2A), but not of JAK1
and STAT5 (data not shown), in a time-dependent manner.
Previous studies have demonstrated that phosphorylated
STAT1 dimerises and translocates into the nucleus to activate
the transcription of a number of genes, including IFN regulatory
factor-1 (IRF-1). IRF-1 functions as a transcriptional factor for
many antiviral genes, resulting in the production of chemokines
(e.g., IP-10) that play critical roles in the infiltration of leukocytes
into the site of inflammation [29]. Additionally, NF-kB dimers
bind to kB sites within the promoter of the IP10 gene [30]. We
therefore examined the transcription of IP-10 and IRF-1 genes in
the HA-challenged A549 cells. As expected, our results showed an
increased transcriptional induction of both genes following HA
exposure (Figure 2B). Correspondingly, we detected a dose-
dependent release of IL-6, IL-8, MCP-1, MIP-1a, MIP-1b and
RANTES into the culture supernatants of the A549 cells 12 h after
HA stimulation, as shown in Figure 2C.
Effect of JAK3 activation on JAK/STAT and NF-kB
signalling pathways in response to HA
Compared with the IFN-triggered JAK/STAT pathway, acti-
vation of JAK3 seems to be a characteristic feature of A/chicken/
Guangdong/191/04 (H5N1) HA-triggered JAK/STAT signalling.
We therefore examined if targeting JAK3 could block the
induction of transcriptional activation of IP-10 and IRF-1 by
HA. As shown in Figure 3A, B, we demonstrated the ability of
the JAK3 inhibitor VI (Calbiochem) to attenuate the phosphor-
ylation of JAK3 while suppressing active NF-kB( Figure 3A)i n
the A549 cells challenged with HA, thus blocking the induction of
IP-10 and IRF-1 gene expression (Figure 3B). In addition, we
also observed significantly lower levels of cytokines/chemokines,
including IL-6, IL-8, MCP-1, MIP-1a, MIP-1b and RANTES, in
the HA-stimulated A549 cells following treatment with the JAK3
inhibitor VI compared to those with HA stimulation alone
(Figure 3C).
Attenuation of the immunopathologic reaction in the
Jak3 knockout mice upon HA challenge
To confirm if the activation of JAK3 enhances HA-driven innate
immunity, Jak3 knockout mice were subjected to challenge with an
intratracheal instillation of HA. In the lung tissues from HA-
challenged Jak3
+/+ mice, pathologic examination observed diffuse
alveolar damage combined with edema, interstitial exudation and
hyaline membrane formation; marked thickening of the interalve-
olar septa; and dense interstitial infiltration by inflammatory cells
(Figure 4A). However, HA-challenged Jak3
2/2 mice (Figure 4C)
or Jak3
+/+ mice treated with JAK3 inhibitor prior to HA addition
(Figure 4E) showed a significant decrease in inflammatory cell
infiltration with a mild injury score (Figure 4F).
In addition, we observed that the spleen tissues from the
Jak3
+/+ mice after 72 h of HA intratracheal instillation exhibited
swelling, destruction of the local structure of germinal centres and
dead lymphocytes (Figure 5Ab, c). These changes were not
observed in Jak3
2/2 mice, which appeared normal despite HA
treatment (Figure 5Ae, f). Compared to the control, the levels of
IFN-c inducible chemokines/cytokines (e.g., IP-10, MCP-1a and
RANTES) released from the splenocytes of the HA-pretreated-
Jak3
+/+ mice were significantly increased under basal conditions
(P,0.05) (Figure 5B), but this effect was not seen in the Jak3
2/2
mice with the HA pretreatment. No significant difference was
detected in the expression levels of chemokines in Jak3
2/2 mice
following either PBS or HA instillation (Figure 5B). Previous
studies have demonstrated that Jak3-dependent cytokine signals
were required for the optimal production of IFN-c in differenti-
ated CD4+ T cells but not for naı ¨ve primary CD4+ T cell
proliferation and cell cycle regulation in vitro, suggesting that these
signals promoted the maximal transcription of the IFNc gene [31].
Taken together, these data indicate that activation of JAK3 signals
by HA of H5N1 has a critical role in inducing an intense host
response.
JAK3: A Drug Target for H5N1-Induced Injury?
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inhibition of JAK3-dependent cytokine signals
Given that the JAK3 inhibitor VI has the capability to down-
regulate NF-kB activation in pulmonary epithelial cells exposed to
HA challenge, we tested whether targeting JAK3 signals could
prevent superinflammatory responses following bacteria/endotox-
in attack. This was tested due to the natural course of the virus,
which is highly cytopathic to bronchial and bronchiolar epithelial
cells, extending rapidly and diffusely down the respiratory tree and
damaging the epithelium sufficiently to breakdown the mucocil-
iary barrier [32].
Both Jak3
+/+ and Jak3
2/2 mice were intratracheally inoculated
with 90 mg HA or PBS. After 72 h of instillation, the spleen cells
were isolated from both groups of mice and cultured in the
presence or absence of bacterial endotoxin-LPS at a concentration
of 10–50 mg for 12 h and 24 h.
In the splenocytes of Jak3
+/+ or Jak3
2/2 mice pretreated with
PBS, the stimulation of LPS induced an increase in levels of
RANTES and MCP-1a (Figure 6A). However, significantly
elevated levels of IP-10, RANTES, IFN-c and MCP-1a were
observed in the splenocytes of HA-pretreated mice upon LPS
challenge (Figure 6B), which were significantly higher in Jak3
+/+
mice than in Jak3
2/2 mice, as shown in Figure 6B. In response
to LPS treatment, the splenocytes from the Jak3
+/+ mice with HA
pretreatment produced higher levels of chemokines/cytokines
compared to the PBS-pretreated mice and to the Jak3
2/2 mice
with HA pretreatment (Figure 6C). We further made a
comparison of the fold increase of the induced chemokines/
cytokines between both groups of Jak3
+/+ and Jak3
2/2 mice.
Except for IFN-c, there was a much lower fold increase of
chemokines/cytokines in the splenocytes with a Jak3 genetic
deficiency compared to those with wild-type Jak3 (Figure 6D).
The injury index of the cultured spleen cells at 12 h (Figure 7A)
or 24 h (Figure 7B) after LPS stimulation was LPS-dose-
dependently higher in the Jak3
+/+ mice than in mice that received
PBS pretreatment only or Jak3
2/2 mice that received the HA
pretreatment (P,0.05) (Figure 7).
These results indicate that sustained JAK3-dependent cytokine
signals following virus antigenic challenge predispose the animal to
an increased virulence for the subsequent bacterial infection.
Discussion
Respiratory infection with highly pathogenic influenza A viruses
is characterised by the exuberant production of cytokines and
Figure 1. Evaluation of the expression and function of recombinant hemagglutinin protein (HA) of AIV H5N1. (A) Preparation of the
recombinant HA protein. Identification of the Bacmid/HA recombinant (a) M, Marker, Lane 1, PCR product of Bacmid-HA. Recombinant HA purified
from Bacmid/HA-transfected SF9 cells by Ni-NTA affinity chromatography (Coomassie Brilliant Blue staining) (b) M, prestained protein marker, Lane1 ,
Control (from SF9 cells transfected with blank bacmid), Lane 2, HA Purified from Bacmid/HA-transfected SF9 cells. Confirmation of HA recombinant by
western blot analysis (c) M, Marker, Lane 1, HA Purified from Bacmid/HA-transfected SF9 cells, Lane 2, control. (B) Morphology changes in the
recombinant HA-treated human pulmonary epithelial cells. A549 cells treated with 40 mg/ml HA (b) or the control (a) for 12 h (bar=50 mm). The cells
treated with HA become swollen, rounded and irregular in size and shape.
doi:10.1371/journal.pone.0031721.g001
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PLoS ONE | www.plosone.org 3 February 2012 | Volume 7 | Issue 2 | e31721chemokines and the enhanced recruitment of innate inflammatory
cells. Although alveolar macrophages were originally described as
the cell type responsible for pulmonary monocyte recruitment
during AIV infection, a recent study by Herold et al. suggests
instead that the majority of the recruitment results from alveolar
epithelial cells that produce high levels of CCL2 (MCP-1), a ligand
for CCR2, following infection [33]. This result is in agreement
with our findings that show activation of JAK/STAT and NF-kB
Figure 2. Impact of H5N1 HA on JAK/STAT and NF-kB signalling in the challenged pulmonary epithelial cells. (A) Detection of
phosphorylated/nonphosphorylated JAK2, JAK3, STAT1 and NF-kB. Using specific antibodies, western blotting was performed in the A549 cells
treated with the HA (40 mg/ml) for the indicated time periods. Representative blots from 3 replicates are shown. (B) The mRNA expression of IP-10
and IRF-1 on the HA-treated A549 cells. A549 cells were treated with the HA (40 mg/ml) for 1–4 h (Lane 1, 0 h; Lane 2, 1 h; Lane 3, 2 h; Lane 4, 4 h) or
with the HA for 1 h at the indicated doses (Lane 5, control; Lane 6, 20 mg/ml; Lane 7, 40 mg/ml; Lane 8, 80 mg/ml) and then subjected to RT-PCR
analysis for IP-10 and IRF-1. Representative gels from 3 replicates are shown. (C) Levels of IL-6, IL-8, MCP-1, MIP-1a, MIP-1b and RANTES in the
supernatant of A549 cells treated with the indicated doses of HA for 12 h. *P,0.05 vs. control group;
#P,0.05 vs. 20 mg/ml HA group; & P,0.05 vs.
40 mg/ml HA group.
doi:10.1371/journal.pone.0031721.g002
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with HA of H5N1 (Figure 2A), leading to rapid induction of the
IP-10 and IRF-1 genes (Figure 2B). In addition, high levels of
cytokines/chemokines were produced (Figure 2C). These data
may represent a mechanism whereby virus antigenic challenge of
alveolar epithelial cells constitutes an initiating event for the
development of dysregulated innate immunity. It is worthwhile to
point out that HA-triggered signalling events are characterised by
an unusual process involved in the phosphorylation of JAK3.
The Janus kinases, including JAK1, JAK2, JAK3 and Tyk2, are
cytoplasmic protein tyrosine kinases that play an important role in
the receptor binding-triggered signal transduction that is mediated
through the STAT proteins [34]. The expression patterns of Janus
kinase 3 contrast sharply with that of other Janus kinases, which
are ubiquitously expressed. JAK3 was found to be more limited in
its expression and is found in nature killer (NK) cells and in an
NK-like cell line but not in resting T cells or in other tissues [35].
In the present study, we have provided evidence that HA
treatment immediately caused phosphorylation of JAK2/3 and
STAT1/NF-kB in A549 cells (Figure 2A) and mediated the
release of cytokines/chemokines (Figure 2C), whereas targeting
to JAK3 can turn off the signal transduction cascades (Figure 3).
Figure 3. The role of JAK3 activation in JAK/STAT and NF-kB signalling upon challenge of HA. (A, B) Modulation of the phosphorylation
of JAK3 and NF-kB and of the expression of the IP-10 and IRF-1 genes in the HA-treated A549 cells in the presence and absence of the JAK3 inhibitor
VI. Western blot analysis (A) and RT-PCR (B) were performed to assess the signal pathways and the gene expression in the A549 cells challenged with
HA (40 mg/ml) for 1 h in the absence and presence of the JAK3 inhibitor VI (760 nM). The measurement of the expression of GAPDH was performed
simultaneously. Representative gels or blots from 3 replicates are shown. (C) Effects of treatment with the JAK3 inhibitor VI on the release of
cytokines/chemokines from the HA-challenged A549 cells. A Liquidchip assay was performed on the supernatants of the A549 cells incubated with
HA (40 mg/ml) for 12 h in the absence and presence of the JAK3 inhibitor VI (760 nM). *P,0.05 vs. control group;
#P,0.05 vs. HA group.
doi:10.1371/journal.pone.0031721.g003
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PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31721Our results suggest that JAK3 is inducible upon activation in type
II pneumocytes. Following the activation of H5N1 by HA,
pulmonary epithelial cells, which actively express JAK3, acquire
the capability for the recruitment of inflammatory monocyte-
derived DC, NK cells and T cells due to significantly increased
release of cytokines/chemokines.
In addition, we show that in Jak3
+/+ mice, but not in Jak3
2/2
mice, the HA intratracheal instillation caused acute injury to lungs
(Figure 4), while necrosis and depletion of lymphocytes were
observed in the spleen (Figure 5A). However, the splenocytes
from HA-pretreated Jak3
+/+ mice were shown to significantly
increase production of IFN-inducible chemokines (e.g., IP10,
MCP1) without any stimulation (Figure 5B). We have previously
demonstrated that the elevation of IP-10 that emerged at the onset
of SARS was followed by progressive lymphopenia with a
concomitant increase of lactate dehydrogenase, suggesting a de-
pletion of lymphocytes in lymphoid tissues [36]. An early onset of
lymphopenia with the pronounced elevation of cytokines/
chemokines and apoptotic lymphocytes in the spleen were also
observed in patients infected with H5N1 influenza virus, especially
those with a severe infection [28]. These data indicate that the
early splenic lymphocyte elimination could occur due to an
excessive innate immune induction that is dependent on Jak3
signal activation following the antigenic challenge of H5N1, which
might contribute to high levels of viral replication.
Activation of NF-kB plays an important role in driving the
inflammatory response due to its function as a critical transcrip-
tional activator of proinflammatory cytokines involved in the
innate immune response to PAMPs/DAMPs [37]. In the present
study, we observed Jak3-dependent signals affecting NF-kB
transcriptional activation upon HA stimulation. The splenocytes
isolated from the Jak3
2/2 mice challenged with HA display a
resistance against the superinflammatory reaction when they are
further exposed to LPS (Figure 6B,C,D and Figure 7A,B),
indicating that active expression of JAK3 might be associated with
the exacerbation of LPS-mediated NF-kB signalling.
Our present results provide evidence that the inhibition of JAK3
activation enables the negative regulation of NF-kB signalling,
further demonstrating that JAK3 is a molecular determinant in the
dysregulated innate immune response.
Previous studies using global immune suppressants (such
as steroids) have failed to demonstrate protection against lethal
influenza virus challenge [38]. It is not surprising that such non-
specific immune suppressants confer no advantage, as a systemic
reduction in cell-mediated immunity greatly compromises virus
clearance. A recent study demonstrated that combination therapy
consisting of an inhibitor of the viral neuraminidase (zanamvir)
and two cyclooxygenase 2 (COX2) inhibitors (celecoxib and
mesalazine) greatly increased the survival rate of mice infected
with a highly pathogenic strain of influenza A/H5N1 virus [39].
Aldridge et al. [40] recently reported that prophylactic treatment
with the PPAR-c agonist pioglitazone is sufficient to reduce
morbidity and mortality associated with HP influenza A virus
infection.
A selective JAK3 inhibitor is considered to be an immunomod-
ulator with extensive application potential because of its specificity
without inducing many of the side effects usually caused by
corticosteroids. Phase I and II clinical trials proved efficacy and
safety of JAK3 inhibition in preventing transplant rejection and
eliminating the symptoms of rheumatoid arthritis and psoriasis.
CP-690550 which has a similar structure to the JAK3 inhibitor VI
[41] used in our study, is currently undergoing Phase III study in
patients with active rheumatoid arthritis [42]. Researchers found
that CP-690550 strongly inhibited the transcription of RANTES,
MIG and IP-10 at 7 days posttransplant [43]. A similar efficiency
of the JAK3 inhibitor VI to modulate the proinflammatory
cytokines/chemokines was observed in vitro and in vivo in the
present studies (Figure 3 and 4).
T cell proliferation following activation is an essential aspect for
the adaptive immune response against pathogens. When T cells
are stimulated under these conditions, their proliferation is cc
cytokine independent [44]. Selective inhibition of Jak3-dependent
cytokine signals did not affect cell cycle progression following
optimal stimulation of T cell receptor plus CD28 [45]. These
could explain our findings that a genetic deficiency in Jak3 pro-
tected splenic lymphocytes from the intense immune-mediated
destruction (Figure 5). We presume that patients with severe
viral infection may benefit from the treatment with selective JAK3
inhibitors that modulate the dysregulation of cytokine-mediated
inflammation but allow T cell proliferation for the adaptive
immune response against pathogens.
It is clear that Influenza A viruses (IAV) induces defects in
respiratory mucosal immunity that are broad-based and adversely
affect the response to a wide range of bacteria. Interactions
between the infecting virus and secondary infections due to
bacteria that colonise the upper respiratory tract could precipitate
the appearance of severe and potentially fatal bacterial pneumonia
Figure 4. Pathological examination of lung tissues in the Jak3-
deficient and wild-type mice following exposure to HA. Jak3
+/+
and Jak3
2/2 mice were administered PBS (B, D) or the HA (90 mg per
mouse) (A, C) by intratracheal instillation. Meanwhile, the JAK3 inhibitor
VI was administered to the Jak3
+/+ mice prior to the HA instillation (E).
Arrows show a marked thickening of the interalveolar septa with
infiltration of lymphocytes (black arrow) and interstitial exudation (red
arrow). The pathological examination (H&E) of lung tissues was
performed at 72 h after HA administration (bar=50 mm). The lung
injury score was assessed in the lung tissues of the mice treated as
above (F) (n=5 per group, , Jak3
+/+ PBS, , Jak3
2/2 PBS, %, Jak3
+/+
HA, &, Jak3
2/2 HA, , Jak3
+/+ HA+JAK3Inh). *P,0.05 vs. Jak3
+/+ PBS
group;
#P,0.05 vs. Jak3
+/+ HA group.
doi:10.1371/journal.pone.0031721.g004
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LPS of PAMPs in splenocytes from mice pretreated with HA
(Figure 6, 7) raise the possibility that following viral antigenic
challenge, bacteria/endotoxin translocation prolongs and boosts
Jak3-dependent cytokine signals, leading to fatal systemic inflam-
matory response syndrome.
Thus, we suggest that the optimal treatment for the virus-
mediated ARDS or/and systemic inflammation may involve
combination therapy with efficacy-based antiviral reagents and
selective Jak3 inhibitors (e.g., JAK3VI inhibitor or CP-690550).
In summary, we found that challenging pulmonary epithelial
cells with the HA from the H5N1 strain of the influenza A virus,
resulting in a remarkable activation of the innate immune response
via triggering IFN-independent JAK/STAT and NF-kB signal
pathways, may be a key mechanism underlying the development
of lung damage and lymphocyte apoptosis that avoids immuno-
surveillance and facilitates efficient viral replication at an early
stage of the illness. JAK3 seems to serve as a central signal
molecular for the transduction of a ‘super-activated’ immune
response to AI-PAMP. We suggest that modulation of the
abnormal innate immune inflammation using a selective JAK3
inhibitor could be a novel and valuable strategy for the mana-
gement of AI-associated severe pneumonia and immune suppres-
sion, even though anti-viral therapy is an important first step in
recovery.
Materials and Methods
Purification of HA protein
Because the baculovirus expression system can produce a high
yield of recombinant protein that is usually similar in structure,
biological activity and immunological reactivity to the naturally
occurring protein, an insect-baculovirus expression system was used
for the expression of the recombinant HA protein of AIV H5N1
using the method described by Nwe et al. with minor modifications
[46]. Using sequence homology, we confirmed that the HA gene of
A/chicken/Guangdong/191/04 (H5N1) (GenBank: AY737289)
[47] was subcloned into the pFastbacHT plasmid vector, forming
a recombinant pFastBacHT-H5HA. Next, pFastBacHT-H5HA
was transposited in combination with a baculovirus shuttle vector
(bacmid) into MAX Efficiency DH10Bac competent cells by
homologous recombination. As predicted, the Bacmid/HA recom-
binant was identified by PCR amplification of a 4.1 KB DNA
fragment (Figure 1Aa) following recombination. Using nickel
affinity magnet beads, the recombinant HA (64 KDa) of H5N1 was
purified from SF9 cells transfected with Bacmid-H5HA and
Figure 5. Pathological examination of splenic tissues in the Jak3
2/2 and Jak3
+/+ mice following exposure to HA. (A) Haematoxylin/
eosin (H&E) staining of paraffin sections of splenic tissues from the Jak3
+/+ and Jak3
2/2 mice intratracheally administered with PBS or HA for 72 h.
Arrows show the necrosis of lymphocytes. (B) The cytokines/chemokines (IFN-c, IP-10, MCP-1a and RANTES) that were released from the splenocytes
of either Jak3
+/+ or Jak3
2/2 mice pretreated with HA or PBS as described above. The measurement of the concentration of the cytokines/chemokines
by Liquidchip assay. *P,0.05 vs. Jak3
+/+ PBS group;
#P,0.05 vs. Jak3
+/+ HA group.
doi:10.1371/journal.pone.0031721.g005
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PLoS ONE | www.plosone.org 7 February 2012 | Volume 7 | Issue 2 | e31721identified by western blotting with an anti-HA (H5N1) anti-
body (Cat. No. GI-003-006, GeneImmune Inc.), as shown in
Figure 1Ab, c.
Mice experiments
B6129S4-Jak3
tm1Ljb mice (Jak3
2/2) and B6129SF2/J mice
(Jak3
+/+) were purchased from Jackson Labs, United States. All
mice were housed at a constant temperature (20uC) with a 12-hour
light/dark photoperiod and allowed food and water ad libitum. The
mice were 6 to 8 weeks of age and weighed between 20 and
30 grams. All animal experiments were carried out according to
the National Institutes of Health Guide for Care and Use of
Laboratory Animals and were approved by the Bioethics
Committee of State Key Laboratory of Respiratory Disease,
Guangzhou Medical University (Approval ID: 2010-12). Briefly,
wild-type or Jak3 knockout mice were randomly divided into
two groups (n=5 in each). After they were anaesthetised with
pentobarbital sodium (50 mg/kg), the mice were intratracheally
inoculated with 90 mg of HA diluted with 100 ml phosphate-
buffered saline (PBS). The control group received an equal volume
of sterilised saline without HA. Lung and spleen tissues from the
mice were collected 72 h after HA inoculation and fixed in
buffered 4% paraformaldehyde (pH 7.4) for histopathological
examination.
Figure 6. Impact of HA intratracheal instillation on the inflammatory reaction of splenocytes from Jak3
2/2 mice. Liquidchip assays
were performed to determine the cytokines/chemokines (IFN-c, MCP-1a, IP-10 and RANTES) released from the splenocytes after LPS (20 mg/ml for
12 h) challenge in PBS-pretreated (A) and HA-pretreated (B) mice of either the Jak3
2/2 or Jak3
+/+ background. (A) *P,0.05 vs. PBS group (Jak3
+/+ or
Jak3
2/2) without LPS treatment;
#P,0.05 vs. Jak3
+/+ PBS group with LPS treatment. (B) *P,0.05 vs. HA group (Jak3
+/+ or Jak3
2/2) without LPS
treatment;
#P,0.05 vs. Jak3
+/+ HA group with LPS treatment. A comparison of the levels of the cytokines/chemokines in the supernatants of the
splenocytes exposed to LPS from Jak3
2/2 and Jak3
+/+ mice with or without HA pretreatment (C). (C) *P,0.05 vs. PBS group (Jak3
+/+ or Jak3
2/2) with
LPS treatment;
#P,0.05 vs. Jak3
+/+ HA group with LPS treatment. A comparison of the fold increase of cytokines/chemokines released from the
splenocytes following LPS stimulation from Jak3
2/2 and Jak3
+/+ mice with HA pretreatment (D).
doi:10.1371/journal.pone.0031721.g006
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A549 cells (A human alveolar epithelial cell line, CCL-185,
ATCC, USA) were grown in 75 cm
2 polystyrene flasks with
DMEM (Gibco, USA) supplemented with 10% heat-inactivated
foetal bovine serum (FBS) (Gibco, NY, USA). A549 cells were
seeded at 1610
6 cells per well in 6-well flat-bottom cell culture
plates (Corning, NY, USA), which produced a confluent monolayer
after overnight incubation at 37uC in a 5% CO2 humidified
atmosphere. Next, the growth medium was replaced with serum-
free DMEM medium and incubated overnight. The cultured A549
cells were either treated with HA or a JAK3 inhibitor VI (760 nM)
for 30 min prior to HA addition. Supernatants were collected 12 h
after incubation with HA at different concentrations and stored at
270uC until cytokine/chemokine detection.
The spleens were removed from the Jak3
+/+ and Jak3
2/2 mice
after the mice were intratracheally inoculated with HA for 72 h.
The spleens were mechanically disrupted by pressing them through
a nylon mesh (pore size, 165 mm) and were deposited in a 25 cm
2
flask containing 5 ml of RPMI 1640 (Invitrogen Life Technologies).
The suspension was passed through a sterile nylon mesh (pore size,
50 mm) to obtain the splenocytes. After the lysis of erythrocytes by
treatment with Tris/NH4Cl buffer, the pooled splenocytes were
suspended with complete tissue culture medium consisting of RPMI
1640 supplemented with 10% of heat-inactivated FBS (Invitrogen
Life Technologies), 100 U/ml penicillin and streptomycin [48].
Western blot analysis
A549 cells were lysed in RIPA buffer [50 mM Tris (pH 7.5),
150 mM NaCl, 1% NP-40, 0.1% SDS, 1 mM EDTA, 1 mM
NaN3, 1 mM PMSF, 2 mg/ml aprotinin, 2 mg/ml leupeptin].
Lysates were cleared by centrifugation, and supernatants were
stored in aliquots at 280uC until further use. The protein was
quantified using a BCA assay kit (Pierce, USA), and 100 mg was
used for SDS-PAGE electrophoresis. After the proteins were
transferred from the gel onto a polyvinylidene fluoride membrane
(DuPont-New England Nuclear, Boston, MA), the membrane
was blocked with 5% non-fat dried milk in Tris-buffered saline
and Tween-20 for 1 h, followed by further incubation of the
membrane with 5% non-fat dried milk containing the primary
antibody at 4uC overnight. Immunodetection of target proteins
was performed with primary antibodies for total or phosphorylated
JAK1, JAK2, JAK3, STAT1 and NF-kB (Cell Signalling,
Frankfurt, Germany). After washing, the secondary antibody
[goat-anti-rabbit IgG conjugated to HRP (Cell Signalling,
Frankfurt, Germany)] was added and incubated for an additional
1 h. Immunoreactive bands were developed using an ECL
chemiluminescent substrate (Pierce, Rockford, USA), and digital
scanning was performed in an Image Station 2000 (Kodak, US).
For all experiments, GAPDH (Novus Biologicals, USA) was
detected simultaneously to confirm equal protein loading.
RT-PCR
After treatment with HA or vehicle for the indicated period,
A549 cells were harvested, and total RNA was isolated using
TriZol Reagent (Invitrogen). Then, the reverse transcription
reaction was conducted using SuperScript
TM III reverse tran-
scription reagents (Invitrogen). We amplified previously generated
cDNA by PCR using the following specific primers for IP-10, IRF-
Figure 7. The effects of injury on the splenocytes challenged with LPS in HA-pretreated Jak3
2/2 mice. The splenocytes isolated from
mice pretreated with HA or intratracheal instillation with PBS for 72 h were treated with LPS for 12 h (A) and 24 h (B), and then the cells were
subjected to a CCK-8 assay for the evaluation of the injury index. The injury index=(OD value of control cells2OD of LPS-treated cells)/control cells
OD. *P,0.05 vs. PBS group (Jak3
+/+ or Jak3
2/2);
#P,0.05 vs. Jak3
+/+ HA group with LPS treatment.
doi:10.1371/journal.pone.0031721.g007
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CAGCA -39 and reverse 59- GGCAGTGGAAGTCCATGAAG -
39; for IRF-1, forward 59- CTTAAGAACCCGGCAACCTC-
TGCCTTC -39 and reverse 59- GATATCTGGCAGGGAGTT-
CATG-39; and for GAPDH, forward 59- GGTGAAGGTCG-
GAGTCAACG -39 and reverse 59-CAAAGTTGTCATGGATG-
ACC-39, with product sizes of 757 bp, 405 bp and 497 bp, res-
pectively. All primers were purchased from Invitrogen (California,
USA). The PCR amplification was performed using a Biometra T-
GRADIENT thermal cycler (Nordic BioSite, Ta ¨by, Sweden) using
the following protocol: reactions were predenatured at 94uC for
120 s, denatured at 94uC for 30 s, then cycled at 55uC for 50 s
and 72uC for 60 s for 30 cycles. PCR amplicons were analysed on
1.5% agarose gels, stained with ethidium bromide, and subse-
quently visualised. To confirm use of equal amounts of RNA in
each experiment, all samples were assessed for GAPDH mRNA
expression.
Luminex assay
The quantification of multiple cytokines/chemokines was
performed using the Luminex assay LiquidChip system (Panomics,
CA, USA), which is a bead-based system for immunoassays that
allows for the simultaneous assaying of multiple analytes in a single
sample [49]. The cytokines/chemokines included IL-2, IL-4, IL-6,
IL-8, tumour necrosis factor a (TNF-a), IFN-c, IP-10, MCP-1,
macrophage inflammatory protein 1 alpha (MIP-1a), MIP-1b and
regulated upon activation normal T cell expressed and secreted
(RANTES). Supernatants of the HA-treated A549 cells were
analysed on a LiquidChip system according to the manufacturer’s
instructions. The isolated splenocytes from the Jak3
+/+ and Jak3
2/
2 mice with or without HA pretreatment were subjected to culture
in the absence or presence of lipopolysaccharide (LPS, 20 mg/ml).
After 12 h or 24 h of culture, the supernatants of the splenocytes
were collected for the LiquidChip assay.
Lung and spleen histology
For analysis by light microscopy, lung and spleen tissues were
fixed with freshly prepared 4% paraformaldehyde in PBS (pH 7.4)
for 36 h and embedded in paraffin. Tissue sections (5 mm) were
stained with haematoxylin and eosin (H&E) to enable the
histological evaluation of lung and spleen tissues. Two investiga-
tors blinded to the group assignments analysed the samples and
determined the level of lung injury according to the semiquanti-
tative scoring outlined below. All lung fields were examined for
each sample at 620 magnification. The assessment of histological
lung injury was performed as follows: 0, normal; 1, ,25% the lung
section exhibits interstitial congestion and inflammatory cell
infiltration; 2, 25–50% the lung section exhibits interstitial con-
gestion and inflammatory cell infiltration; 3, 50–75% the lung
section exhibits consolidation and inflammatory cell infiltration.
The mean score was used for the comparison between groups.
Lymphocyte injury assay
The isolated spleen cells (1610
6 per well) were seeded into 96-
well tissue culture plates and stimulated with LPS at different
concentrations (10, 20 or 50 mg) or PBS for 12 or 24 h at 37uC
and 5% CO2; 2-[2-methoxy-4-nitrophenyl]-3-[4-nitrophenyl]-5-
[2,4-disulfophenyl]-2H-tetrazolium monosodium salt (WST-8,
Cell-Counting Kit-8H (Dojindo Molecular Technologies, Inc.,
Gaithersburg, MD) 10 ml per well) was added as described pre-
viously [50]. The plates were incubated for 4 h, and the optical
density (OD) at 450 nm was measured using a microplate reader
(BioRad, Hercules, CA). Each sample was analysed in three
replicates, and the injury index was calculated using the following
formula: injury index=(mean OD of control group–LPS-stimu-
lated group)/(mean OD of control group).
Statistical analysis
Comparisons among treatment groups were performed with a
one-way-ANOVA test. A P value less than 0.05 was considered
statistically significant.
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